Press Release - September 22, 2016
Heidelberg, Germany, September 22, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 29, 2016 at 1:30 p.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the Webcast section on the Affimed website. A replay of the presentation will be available from Affimed’s website for 30 days following the respective conference.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required